7 results about "Hcv hepatitis c virus" patented technology

The present disclosure provides immunogenic compositions comprising one or more T-cell epitope polypeptides, or a fusion polypeptide comprising two or more T-cell epitope polypeptides. The present disclosure provides a method for inducing an immune response to hepatitis C virus in an individual, the method comprising administering to the individual an immunogenic composition of the present disclosure.

The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.

Methods of identifying virus antigens are provided. In particular the antigens induce broadly neutralizing antibodies in Hepatitis C virus infections. Compositions for inducing an immune response are identified by the methods described herein.

Provided herein are compositions and methods that allow for controlled interaction between a target protein and a polypeptide to which a binding protein is fused. Compositions and methods utilize a target protein that binds to the hepatitis C virus protease inhibitor glaprevir to form a complex, and a Tn3 binding protein that specifically binds to the complex. The target protein is or is derived from a viral protease, such as an HCV NS3 / 4A protease.

Attenuated forms of virulent Zika virus and Hepatitis C virus are provided. Vaccine compositions comprising the attenuated virus and methods of eliciting a protective immune response in a subject by administering the vaccine compositions are also provided.

The present invention relates to the field of vaccination, in particular, of vaccination against hepatitis C virus (HCV). The present invention provides a composition comprising HCV glycoprotein E2 from strain GT4a.ED43, and optionally, further HCV glycoproteins E2 from other strains and / or an adjuvant. The glycoprotein can be soluble glycoprotein or it can be displayed on the surface of a nanoparticle. Alternatively, it provides a composition comprising a nucleic acid encoding HCV glycoprotein E2 from strain GT4a.ED43, and, optionally, from other strains. The composition is useful as a vaccine, e.g., for prophylactic vaccination against HCV. The invention also provides a method for producing said composition as well as HCV glycoprotein E2 from strain GT2b.2b5 and a nucleic acid encoding the same.

Hepatitis C virus (HCV) soluble fusion immunogens (sE1E2) that are derived from engineered or redesigned HCV sE1 and sE2 polypeptides and are configured to form a native-like E1E2 interface are provided that can be used in vaccine formulations. Also provided are related vaccine compositions that exhibit the engineered sE1E2 immunogen on a self-assembled nanoparticle scaffold after cleavage to a sE1E2 protein having a native E1E2 conformation. Also provided are methods of using the immunogens and vaccine compositions in methods for preventing or treating HCV infection.